FDA Grants EpiCept Corporation (EPCT) Permission to Initiate AmiKet Phase III Clinical Development
Tweet
Share
E-mailGet Alerts EPCT Hot Sheet
Join SI Premium – FREE
EpiCept Corporation (Nasdaq: EPCT) today announced that at a meeting earlier this week with the U.S. Food and Drug Administration, the Company was granted permission to initiate immediately the Phase III clinical development of AmiKet. AmiKet is a prescription topical cream intended for the treatment of chemotherapy-induced peripheral neuropathyfollowing taxane-based therapy.
Jack Talley, EpiCept President and CEO, commented, “The guidance we received from the FDA during our End of Phase II meeting will permit a quick initiation of AmiKet’s remaining clinical development required for a new drug application (NDA). Every year, millions of cancer survivors suffer from the effects of their chemotherapy, and no treatment is yet approved to treat CIPN. AmiKet™ represents a potentially significant benefit to patients suffering from this painful indication, and may address an unmet medical need that is well recognized.”
The FDA indicated that a CIPN treatment protocol submitted by the Company will be reviewed expeditiously for a Special Protocol Assessment.
The Company has submitted its draft meeting minutes for FDA concurrence and upon receipt of the FDA official meeting minutes will provide more details regarding the clinical and non-clinical package required prior to an NDA filing.
Jack Talley, EpiCept President and CEO, commented, “The guidance we received from the FDA during our End of Phase II meeting will permit a quick initiation of AmiKet’s remaining clinical development required for a new drug application (NDA). Every year, millions of cancer survivors suffer from the effects of their chemotherapy, and no treatment is yet approved to treat CIPN. AmiKet™ represents a potentially significant benefit to patients suffering from this painful indication, and may address an unmet medical need that is well recognized.”
The FDA indicated that a CIPN treatment protocol submitted by the Company will be reviewed expeditiously for a Special Protocol Assessment.
The Company has submitted its draft meeting minutes for FDA concurrence and upon receipt of the FDA official meeting minutes will provide more details regarding the clinical and non-clinical package required prior to an NDA filing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
- Tiziana Life Sciences (TLSA) Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today
- Bio-Path Holdings (BPTH) Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
